Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 175, Issue -, Pages 103705
Publisher
Elsevier BV
Online
2022-05-13
DOI
10.1016/j.critrevonc.2022.103705
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
- (2021) Emma H. A. Stahlie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
- (2021) Julia Maria Ressler et al. Journal for ImmunoTherapy of Cancer
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
- (2021) A. Ribas et al. ANNALS OF ONCOLOGY
- Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
- (2020) Anne Fröhlich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
- (2020) Alexander C. J. van Akkooi et al. ADVANCES IN THERAPY
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Correlates of response and outcomes with talimogene laherperpvec
- (2019) Alice Y. Zhou et al. JOURNAL OF SURGICAL ONCOLOGY
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size
- (2019) Sabran J. Masoud et al. ANNALS OF SURGICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
- (2018) Peter Mohr et al. ADVANCES IN THERAPY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Oncolytic herpes simplex virus interactions with the host immune system
- (2016) Dipongkor Saha et al. Current Opinion in Virology
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
- (2016) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started